



March 27, 2025

Yongfeng (Jack) Y. Zhang, Ph.D.  
CEO, Amphastar Pharmaceuticals, Inc.  
William (Bill) J. Peters, M.B.A.  
President, International Medication Systems, Ltd.  
1886 Santa Anita Avenue  
South El Monte, CA 91733-3414

Dear Dr. Zhang and Mr. Peters:

The U.S. Food and Drug Administration (FDA or the Agency) is pleased to announce that International Medication Systems, Ltd. (IMS), a subsidiary of Amphastar Pharmaceuticals, Inc. (Amphastar) has been selected to receive a Drug Shortage Assistance Award for its role in preventing or alleviating drug shortages.

IMS/Amphastar is being recognized for its efforts to mitigate and resolve the long-standing drug shortage of epinephrine injection, 0.1 mg/mL syringes, including submitting and obtaining approval of a new drug application for epinephrine injection (NDA 211363).

FDA established this award program to recognize companies for making a substantial contribution to preventing or alleviating a drug shortage, demonstrating their commitment to public health and quality manufacturing. FDA hopes this award serves as an incentive for other companies to assist in addressing drug shortages, as IMS/Amphastar has done.

FDA thanks IMS/Amphastar for helping to mitigate and resolve the shortage of epinephrine injection, 0.1 mg/mL syringes. The enclosed press release/web statement template is provided to assist you in publicizing your award from FDA.

Sincerely,

Jacqueline Corrigan-Curay, J.D., M.D.  
Acting Center Director  
FDA, Center for Drug Evaluation and Research

Enclosure(s):  
Certificate  
Optional Press Release/Web Statement Template

cc: Tony D. Marrs, MPH, Executive VP of Regulatory Affairs, Sr. VP of Clinical Operations, Amphastar  
Gisela A. Sharp, Associate Director of Regulatory Affairs, Amphastar